90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Recruiting now · Not applicable

Conditions studied: Carcinoma, Hepatocellular

In brief

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.

Key facts

Study ID

NCT05953961

Run by

Ochsner Health System

People needed

50

Starts

2023-08-08

Expected to finish

2027-01-01

Last updated by the study team

2025-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines
• Eastern Cooperative Oncology Group score 0 - 1
• Child-Pugh A - B
• Bilirubin < 2.5 mg/dL
• Creatinine < 2.0 mg/dL
• No prior liver-directed therapy or systemic therapy for HCC
• Solitary, unresectable HCC ≤ 3cm
• Albumin level < 3.4 g/dL at HCC diagnosis
• Tumor anatomical location and angiosome amendable to MWA and 90Y

You may not qualify if…

• Pregnant women
• Concurrent malignancy

Where it is running

• Ochsner Main Campus — New Orleans, Louisiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.